AI in clinical trials is addressing the challenges of escalating data complexity and accelerated timelines. AI in clinical trials is being used to handle increasing complexity, larger volumes of data, ...

During the discussion, he explained what he wants patients to understand about participating in clinical trials for their gastrointestinal cancers. Additionally, he imparted key updates from this ...

Over recent decades, advances in cancer treatment have yielded substantial improvements in patient outcomes, driving up survival, and even rendering some cancers curable. These advances have been ...

To keep research teams informed of the latest updates to ClinicalTrials.gov, the University at Buffalo Clinical and Translational Science Institute (CTSI) will be providing news about the ...

For decades, the idea of a drug that could rewind aspects of human aging has belonged more to science fiction than hospital formularies. That boundary is starting to blur as a gene therapy called ...

The "TIGIT Inhibitors Drugs Clinical Trials & Global Market Opportunity Outlook 2026" report has been added to ResearchAndMarkets.com's offering. This report tracks developments currently taking place ...

The chronic and acute pain clinical trial analysis report delivers important insights into ongoing research of 200+ pipeline chronic and acute pain drugs, clinical strategies, upcoming therapeutics, ...

CNSide Diagnostics will present data from the FORESEE trial showcasing the CNSide CSF Assay Platform’s utility in diagnosing and guiding clinical decision making for breast cancer and non-small cell ...

MYC targeted therapies offer significant market opportunities, driven by their potential as oncogenic drivers in diverse tumors. The field sees growing R&D on innovative platforms, early-stage ...

Increasing the number of clinical trials at the University at Buffalo is an important goal at the university and at UB’s Clinical and Translational Science Institute (CTSI). This is why boosting the ...

AUSTIN, Texas, Nov. 22, 2024 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, Inc. (PSTV) (Nasdaq: PSTV) (“Plus” or the “Company”), will present data from ...